Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	IQVIA	Bitcoin Group	Charles River Laboratories International	Exact Sciences	Incyte
Symbol	NYSE:IQV	OTCMKTS:BTGGF	NYSE:CRL	NASDAQ:EXAS	NASDAQ:INCY
Price Information
Current Price	$262.27	$48.00	$455.04	$98.22	$69.78
50-Day Moving Average	$253.83	$42.31	$421.64	$104.37	$75.54
52-Week Low	$146.00	$25.63	$205.97	$71.86	$68.82
52-Week High	$265.34	$69.50	$458.27	$159.54	$101.47
MarketRank™
Overall Score	2.0	0.9	2.1	2.5	2.9
Analysis Score	2.5	0.0	2.4	4.4	3.2
Community Score	4.7	4.3	4.3	5.0	5.0
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	1.7	0.0	2.5	2.5	3.3
Earnings & Valuation Score	1.3	0.0	1.3	0.6	3.1
Analyst Ratings
Consensus Recommendation	Buy	N/A	Buy	Buy	Hold
Consensus Price Target	$262.18	N/A	$399.83	$151.06	$91.29
% Upside from Price Target	-0.04% downside	N/A	-12.13% downside	53.80% upside	30.82% upside
Trade Information
Market Cap	$50.25 billion	$18.55 billion	$22.93 billion	$16.89 billion	$15.41 billion
Beta	1.42	0.26	1.14	1.29	0.76
Average Volume	896,554	386	422,178	1,541,308	1,271,133
Sales & Book Value
Annual Revenue	$11.36 billion	N/A	$2.92 billion	$1.49 billion	$2.67 billion
Price / Sales	4.42	N/A	7.84	11.32	5.78
Cashflow	$13.17 per share	N/A	$13.40 per share	$1.49 per share	N/A
Price / Cash	19.92	N/A	33.96	65.70	N/A
Book Value	$32.76 per share	N/A	$42.55 per share	$18.77 per share	$11.92 per share
Price / Book	8.01	N/A	10.69	5.23	5.85
Profitability
Net Income	$279 million	N/A	$364.30 million	$-848,530,000.00	$-295,700,000.00
EPS	$6.03	N/A	$8.13	($1.38)	($1.06)
Trailing P/E Ratio	84.06	0.00	58.64	N/A	45.91
Forward P/E Ratio	27.90	∞	38.83	N/A	20.05
P/E Growth	2.43	N/A	3.07	N/A	0.88
Net Margins	4.69%	N/A	12.10%	-50.52%	12.41%
Return on Equity (ROE)	23.95%	N/A	23.59%	-8.93%	15.77%
Return on Assets (ROA)	6.03%	N/A	8.66%	-4.86%	11.66%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	2.11%	N/A	1.17%	0.53%	0.01%
Current Ratio	1.05%	N/A	1.36%	2.47%	3.97%
Quick Ratio	1.05%	N/A	1.15%	2.34%	3.94%
Ownership Information
Institutional Ownership Percentage	87.01%	N/A	93.28%	88.31%	91.98%
Insider Ownership Percentage	1.10%	N/A	1.20%	1.40%	15.80%
Miscellaneous
Employees	70,000	27	18,400	5,000	1,773
Shares Outstanding	191.61 million	386.49 million	50.40 million	171.95 million	220.84 million
Next Earnings Date	10/19/2021 (Estimated)	N/A	11/4/2021 (Estimated)	10/26/2021 (Estimated)	11/4/2021 (Estimated)
Optionable	Optionable	Not Optionable	Optionable	Optionable	Optionable

Source	Headline
	Expert Ratings For Incyte - Benzinga - Benzinga benzinga.com - September 23 at 5:46 PM
	Incyte on a Roll with Two FDA Wins in Two Days - BioSpace biospace.com - September 23 at 5:46 PM
	Incyte, Knight Therapeutics Ink Distribution Pact For Two Cancer Drugs In Latin America - Yahoo Finance finance.yahoo.com - September 23 at 5:46 PM
	Incyte Corporation (INCY) Stock Declines -7.44% This Week; Should You Buy? - InvestorsObserver investorsobserver.com - September 23 at 12:46 PM
	Incyte : Stifel Adjusts Incyte's Price Target to $85 from $93, Keeps Hold Rating - marketscreener.com marketscreener.com - September 23 at 12:46 PM
	Incyte Corporation Provides Revenue Guidance for the Year 2022 - marketscreener.com marketscreener.com - September 23 at 12:46 PM
	Incyte Sinks After Skin Cream Wins Approval With a Warning (1) - Bloomberg Law news.bloomberglaw.com - September 23 at 12:46 PM
	Knight Therapeutics Enters into Exclusive Supply and Distribution Agreement with Incyte for Tafasitamab and Pemigatinib in Latin America - Yahoo Finance finance.yahoo.com - September 23 at 12:46 PM
	Incyte and Knight Therapeutics ink exclusive supply and distribution agreement - Seeking Alpha seekingalpha.com - September 23 at 12:46 PM
	On a JAK roll, Incyte wins FDA green light to expand Jakafi in chronic graft-versus-host disease - FiercePharma fiercepharma.com - September 23 at 12:46 PM
	Morgan Stanley Cuts Incyte (NASDAQ:INCY) Price Target to $80.00 americanbankingnews.com - September 23 at 11:04 AM
	Incyte (NASDAQ:INCY) PT Lowered to $86.00 americanbankingnews.com - September 23 at 9:38 AM
	Incyte (NASDAQ:INCY) PT Lowered to $80.00 at Morgan Stanley marketbeat.com - September 23 at 9:20 AM
	Incyte (NASDAQ:INCY) Lowered to Market Perform at SVB Leerink americanbankingnews.com - September 23 at 9:02 AM
	Inctye's ruxolitinib scores its second approval in two days, this time in chronic graft-versus-host disease - Endpoints News endpts.com - September 23 at 7:35 AM
	Incyte : SEC Charges Former Executive With Insider Trading On A Misappropriation Theory—With A Twist - marketscreener.com marketscreener.com - September 23 at 7:35 AM
	Knight Therapeutics Enters into Exclusive Supply and Distribution Agreement with Incyte for Tafasitamab and Pemigatinib in Latin America - GlobeNewswire globenewswire.com - September 23 at 7:35 AM
	Incyte (NASDAQ:INCY) Sets New 12-Month Low at $69.42 americanbankingnews.com - September 23 at 2:16 AM
	Incyte Announces FDA Approval of Jakafi® (ruxolitinib) for Treatment of Chronic Graft-Versus-Host Disease (GVHD) - Business Wire businesswire.com - September 22 at 10:55 PM
	Incyte Announces FDA Of Jakafi For Treatment Of Chronic Graft-Versus-Host Diseases - Benzinga benzinga.com - September 22 at 5:55 PM
	Recon: FDA approves Incyte's eczema cream with boxed warnings; Biden pledges 500M doses of Pfizer vaccine - Regulatory Focus raps.org - September 22 at 5:55 PM
	Incyte Announces FDA Approval of Jakafi® (ruxolitinib) for Treatment of Chronic Graft-Versus-Host Disease (GVHD) - Maryville Daily Times thedailytimes.com - September 22 at 5:55 PM
	Incyte eczema drug wins FDA OK, but with safety warning - BioPharma Dive biopharmadive.com - September 22 at 5:55 PM
	Back To Back FDA Approval For Incyte - This Time For Jakafi In GVHD benzinga.com - September 22 at 2:07 PM
	FDA approves Incyte's Jakafi in chronic graft-versus-host disease indication seekingalpha.com - September 22 at 1:46 PM
	FDA approves Incyte's Jakafi in chronic graft-versus-host disease indication - Seeking Alpha seekingalpha.com - September 22 at 12:54 PM
	Incyte (NASDAQ:INCY) Rating Lowered to C+ at TheStreet marketbeat.com - August 24 at 7:13 AM
	3 S&P 500 Laggards Ready to Run marketbeat.com - July 29 at 10:40 AM

Date	Company	Brokerage	Action
9/23/2021	Incyte	Morgan Stanley	Lower Price Target
9/23/2021	Incyte	Royal Bank of Canada	Lower Price Target
9/10/2021	IQVIA	Argus	Boost Price Target
8/23/2021	Charles River Laboratories International	Argus	Boost Price Target
8/17/2021	Charles River Laboratories International	UBS Group	Boost Price Target
8/5/2021	Charles River Laboratories International	Credit Suisse Group	Boost Price Target
8/5/2021	Charles River Laboratories International	Wells Fargo & Company	Boost Price Target
8/5/2021	Charles River Laboratories International	Robert W. Baird	Boost Price Target
8/4/2021	Incyte	SVB Leerink	Lower Price Target
7/29/2021	Exact Sciences	Stifel Nicolaus	Lower Price Target
7/29/2021	Exact Sciences	BTIG Research	Lower Price Target
7/29/2021	Exact Sciences	Canaccord Genuity	Lower Price Target
7/29/2021	Exact Sciences	Oppenheimer	Lower Price Target
7/29/2021	Exact Sciences	Robert W. Baird	Lower Price Target
7/28/2021	IQVIA	Morgan Stanley	Boost Price Target
7/28/2021	IQVIA	Mizuho	Boost Price Target
7/28/2021	IQVIA	Piper Sandler	Boost Price Target
7/28/2021	IQVIA	Deutsche Bank Aktiengesellschaft	Boost Price Target
7/28/2021	IQVIA	Citigroup	Boost Price Target
7/28/2021	IQVIA	Robert W. Baird	Boost Price Target
7/20/2021	IQVIA	Credit Suisse Group	Boost Price Target
7/20/2021	Charles River Laboratories International	Credit Suisse Group	Boost Price Target
7/20/2021	Incyte	Benchmark	Upgrade
7/14/2021	Exact Sciences	SVB Leerink	Lower Price Target
7/13/2021	IQVIA	Barclays	Boost Price Target
6/25/2021	Incyte	Royal Bank of Canada	Lower Price Target
6/21/2021	Exact Sciences	Wells Fargo & Company	Boost Price Target
6/15/2021	Exact Sciences	Raymond James	Initiated Coverage
6/15/2021	Incyte	William Blair	Reiterated Rating
6/15/2021	Incyte	SVB Leerink	Reiterated Rating
6/3/2021	Exact Sciences	The Goldman Sachs Group	Initiated Coverage
5/31/2021	Charles River Laboratories International	Robert W. Baird	Reiterated Rating
5/28/2021	Charles River Laboratories International	Credit Suisse Group	Boost Price Target
5/28/2021	Charles River Laboratories International	JPMorgan Chase & Co.	Boost Price Target
5/28/2021	Charles River Laboratories International	Citigroup	Boost Price Target
5/25/2021	Charles River Laboratories International	Truist Securities	Boost Price Target
5/25/2021	Exact Sciences	Wells Fargo & Company	Initiated Coverage
5/14/2021	IQVIA	KeyCorp	Boost Price Target
5/14/2021	Charles River Laboratories International	KeyCorp	Boost Price Target
5/12/2021	IQVIA	Canaccord Genuity	Boost Price Target
5/12/2021	IQVIA	Argus	Boost Price Target
5/12/2021	Exact Sciences	Truist	Lower Price Target
5/12/2021	Exact Sciences	Truist Securities	Lower Price Target
5/5/2021	Charles River Laboratories International	Deutsche Bank Aktiengesellschaft	Boost Price Target
5/5/2021	Charles River Laboratories International	Robert W. Baird	Boost Price Target
5/5/2021	Exact Sciences	Craig Hallum	Lower Price Target
5/5/2021	Exact Sciences	BTIG Research	Lower Price Target
5/5/2021	Exact Sciences	SVB Leerink	Lower Price Target
5/5/2021	Incyte	Morgan Stanley	Lower Price Target
4/26/2021	IQVIA	Truist	Boost Price Target
4/26/2021	IQVIA	Truist Securities	Boost Price Target
4/26/2021	IQVIA	Morgan Stanley	Boost Price Target
4/26/2021	IQVIA	Barclays	Boost Price Target
4/23/2021	IQVIA	Citigroup	Boost Price Target
4/23/2021	IQVIA	Jefferies Financial Group	Boost Price Target
4/23/2021	IQVIA	Robert W. Baird	Boost Price Target
4/23/2021	IQVIA	Deutsche Bank Aktiengesellschaft	Boost Price Target
4/23/2021	IQVIA	Mizuho	Boost Price Target
4/16/2021	IQVIA	Stephens	Upgrade
4/9/2021	IQVIA	Mizuho	Boost Price Target
4/5/2021	Incyte	Morgan Stanley	Lower Price Target
3/15/2021	IQVIA	KeyCorp	Upgrade
3/8/2021	IQVIA	Barclays	Initiated Coverage
2/25/2021	Charles River Laboratories International	Morgan Stanley	Boost Price Target
2/18/2021	Charles River Laboratories International	Truist	Boost Price Target
2/18/2021	Charles River Laboratories International	Credit Suisse Group	Boost Price Target
2/18/2021	Charles River Laboratories International	Deutsche Bank Aktiengesellschaft	Boost Price Target
2/18/2021	Exact Sciences	Robert W. Baird	Lower Price Target
2/17/2021	Exact Sciences	Stifel Nicolaus	Boost Price Target
2/17/2021	Exact Sciences	SVB Leerink	Boost Price Target
2/17/2021	Exact Sciences	Cowen	Boost Price Target
2/10/2021	Incyte	Morgan Stanley	Lower Price Target
2/10/2021	Incyte	SVB Leerink	Downgrade
1/27/2021	Exact Sciences	Truist	Initiated Coverage
1/21/2021	Exact Sciences	SVB Leerink	Boost Price Target
1/12/2021	Exact Sciences	Canaccord Genuity	Boost Price Target
1/7/2021	Incyte	Truist	Initiated Coverage
1/4/2021	Incyte	Guggenheim	Upgrade
12/22/2020	Charles River Laboratories International	Argus	Boost Price Target
12/16/2020	Charles River Laboratories International	Smith Barney Citigroup	Downgrade
11/24/2020	Charles River Laboratories International	KeyCorp	Boost Price Target
11/9/2020	Incyte	Morgan Stanley	Lower Price Target
11/6/2020	Incyte	BMO Capital Markets	Lower Price Target
11/6/2020	Incyte	Royal Bank of Canada	Lower Price Target
11/3/2020	Charles River Laboratories International	Truist	Boost Price Target
10/30/2020	Charles River Laboratories International	Morgan Stanley	Boost Price Target
10/30/2020	Charles River Laboratories International	Deutsche Bank Aktiengesellschaft	Boost Price Target
10/29/2020	Exact Sciences	UBS Group	Downgrade
10/28/2020	Exact Sciences	Canaccord Genuity	Boost Price Target
10/28/2020	Exact Sciences	Oppenheimer	Boost Price Target
10/15/2020	Incyte	Bank of America	Lower Price Target
10/13/2020	Incyte	Morgan Stanley	Boost Price Target
9/14/2020	Charles River Laboratories International	Argus	Boost Price Target
8/9/2020	Incyte	Cowen	Reiterated Rating
8/6/2020	Incyte	BMO Capital Markets	Boost Price Target
8/6/2020	Incyte	Credit Suisse Group	Lower Price Target
8/6/2020	Incyte	Morgan Stanley	Boost Price Target
8/4/2020	Incyte	Mizuho	Initiated Coverage
8/4/2020	Incyte	SVB Leerink	Boost Price Target
8/3/2020	Incyte	Royal Bank of Canada	Boost Price Target
11/30/2018	Bitcoin Group	Jefferies Financial Group	Downgrade
11/26/2018	Bitcoin Group	Stifel Nicolaus	Reiterated Rating

(Data available from 9/23/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources